GeneDx Holdings Corp. (NASDAQ:WGS) Receives $138.13 Consensus PT from Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $138.1250.

A number of analysts have commented on the stock. BTIG Research upped their price target on shares of GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Wall Street Zen cut GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Wells Fargo & Company set a $155.00 price objective on shares of GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $170.00 price target (up from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th.

GeneDx Stock Down 7.9%

Shares of WGS opened at $109.84 on Friday. The company has a market capitalization of $3.18 billion, a PE ratio of 1,220.44 and a beta of 2.01. The stock’s 50-day moving average price is $142.51 and its two-hundred day moving average price is $123.53. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. GeneDx has a 12 month low of $55.17 and a 12 month high of $170.87.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The business had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. On average, analysts anticipate that GeneDx will post 0.97 EPS for the current year.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Company set FY‑2026 revenue guidance of $540.0M–$555.0M, above the street consensus of ~$529.2M — implies continued top‑line growth and supports longer‑term revenue trajectory. Article Title
• Positive Sentiment: Strategic partnership with Komodo Health to link GeneDx’s genomic data with real‑world clinical insights — strengthens data monetization opportunities and rare‑disease research capabilities, which can add recurring revenue and differentiation. Article Title
• Neutral Sentiment: Company released preliminary 2025 financial results and updated Q4/FY‑2025 revenue guidance that were roughly in line with consensus (FY‑2025 revenue guidance ~ $427.0M vs. ~$426.5M consensus) — suggests stability but not a material beat on profit metrics. Article Title
• Neutral Sentiment: Reported short‑interest data shows zero shares shorted (days‑to‑cover 0.0), which appears to be a data anomaly and is unlikely to be driving the move. (No clear short‑squeeze dynamics indicated.)
• Negative Sentiment: Market reaction was negative: multiple reports note the stock fell after the 2026 guidance disappointed investors. The disappointment appears driven by a guidance mix — revenue guidance was constructive, but the company either left EPS guidance blank or provided limited profit/margin clarity, leaving investors uncertain on near‑term profitability and cadence of margin improvement. Article Title Article Title

Insider Transactions at GeneDx

In related news, CEO Katherine Stueland sold 10,857 shares of GeneDx stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total value of $1,562,213.73. Following the completion of the sale, the chief executive officer owned 14,237 shares of the company’s stock, valued at approximately $2,048,561.93. This trade represents a 43.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Joshua Ruch sold 38,000 shares of GeneDx stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $160.37, for a total value of $6,094,060.00. Following the transaction, the director owned 11,941 shares of the company’s stock, valued at $1,914,978.17. This trade represents a 76.09% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 60,163 shares of company stock valued at $9,339,792 over the last ninety days. 29.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC boosted its holdings in shares of GeneDx by 937.3% in the fourth quarter. SG Americas Securities LLC now owns 63,181 shares of the company’s stock worth $8,217,000 after acquiring an additional 57,090 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of GeneDx by 1,358.7% in the fourth quarter. Assenagon Asset Management S.A. now owns 205,895 shares of the company’s stock valued at $26,779,000 after acquiring an additional 191,780 shares during the period. Avior Wealth Management LLC bought a new position in shares of GeneDx in the fourth quarter valued at approximately $224,000. JPMorgan Chase & Co. grew its stake in GeneDx by 37.6% during the third quarter. JPMorgan Chase & Co. now owns 27,794 shares of the company’s stock valued at $2,995,000 after acquiring an additional 7,592 shares in the last quarter. Finally, CIBC Bancorp USA Inc. bought a new stake in GeneDx during the 3rd quarter worth approximately $216,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.